ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

ImmunityBio Inc. (NASDAQ:IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth. This surge follows a strong performance driven by the sales of its lead drug, Anktiva, which has gained traction in the market.The stock has jumped over 50% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.Anktiva Sales Surge: 750% Unit IncreaseImmunityBio reported a remarkable year-ove ...